Overview

Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-20

Target enrollment:

Participant gender:

Summary

This study is a prospective, single arm phase II clinical trial ,aimed at exploring the efficacy and safety of the combination therapy of anti-PD-1 and VEGF bispecific antibody Ivonescimab combined with chemotherapy as first-line treatment of relapsed or metastatic thymic cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Drug Therapy